Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pd-1 inhibitor + ICE
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
The combination "pd-1 inhibitor + ICE" refers to the concurrent use of a programmed death 1 (PD-1) immune checkpoint inhibitor (such as pembrolizumab) with the chemotherapy regimen known as ICE—ifosfamide, carboplatin, and etoposide. This combination is primarily investigated for relapsed or refractory hematologic malignancies such as classical Hodgkin lymphoma and diffuse large B-cell lymphoma. The PD-1 inhibitor blocks the interaction between PD-1 on T cells and its ligands on tumor cells, thereby enhancing anti-tumor immune responses. The chemotherapy components act by damaging DNA in rapidly dividing cancer cells[3][6].
- Other names
- pembrolizumab + ICEPD-1 inhibitor plus ifosfamide/carboplatin/etoposidePD-1 inhibitor with ICE chemotherapyPD1 inhibitor with ICE chemotherapyPD 1 inhibitor with ICE chemotherapy
02
Targets
DNATOP2A (DNA topoisomerase II)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pd-1 inhibitor + ICE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pd-1 inhibitor + ICE.